Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCCG infant ALL/MPAL 2022 protocol with venetoclax and blinatumomab
ChiCTR2200064906Phase 3Not yet recruiting
- Sponsor
- Children's Hospital of Soochow University
- Start
- Oct 2022
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of venetoclax and blinatumomab in acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL) (2 arms), sponsored by Children's Hospital of Soochow University. Primary endpoints: overall survival, event-free survival and 2 more. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
venetoclaxblinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on ChiCTR2200064906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064906.